Breaking News Instant updates and real-time market news.

TEVA

Teva

$45.19

-0.07 (-0.15%)

08:01
10/06/16
10/06
08:01
10/06/16
08:01

Teva, Celltrion announce exclusive biosimilar commercial relationship

Teva Pharmaceutical, Celltrion, Inc. and Celltrion Healthcare announce that the companies have entered into an exclusive partnership to commercialize two of Celltrion's mAb biosimilar candidates in the U.S. and Canada. CT-P10 is a proposed mAb biosimilar to Rituxan, which is used to treat patients with Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Wegener's Granulomatosis and Microscopic Polyangiitis. CT-P6 is a proposed mAb biosimilar to Herceptin, which is used for the treatment of HER2-overexpressing breast cancer and for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Combined annual net sales for Rituxan and Herceptin are approximately $6.5B in the U.S. and Canada. Both CT-P10 and CT-P6 are currently in late-stage Phase III development and their primary endpoints have been successfully achieved. CT-P10 was submitted by Celltrion to the European Medicines Agency for review in October 2015. In the meantime, Celltrion is preparing CT-P6 for submission in Europe seeking approval from the EMA this quarter. As part of the agreement, Teva will be responsible for all commercial activities in the U.S. and Canada, pending regulatory approvals for both products. Celltrion has responsibility for completing all clinical development and regulatory activities. Under the terms of the agreement, Teva will pay Celltrion Healthcare $160M upfront of which up to $60M is refundable or creditable under certain circumstances. Teva and Celltrion Healthcare will share profit from the commercialization of the mAb biosimilars.

  • 06

    Nov

  • 15

    Nov

TEVA Teva
$45.19

-0.07 (-0.15%)

09/23/16
LEER
09/23/16
NO CHANGE
LEER
Outperform
Positive data paves way for Teva SD-809 indication, says Leerink
Leerink analyst Jason Gerberry says the AIM-TD study readout clinically de-risks Teva's (TEVA) SD-809 opportunity for tardive dyskinesia, with the investor focus shifting to market size and competitive differentiation versus Neurocrine's (NBIX) valbenazine. The analyst believes Teva's SD-809 is well positioned to compete against valbenazine with an equally efficacious and well tolerated drug. Further, he expects Teva to exit 2017 with a broader label. Gerberry reiterates an Outperform rating on Teva's shares.
09/29/16
OTRG
09/29/16
INITIATION
OTRG
Positive
Teva initiated with a Positive at OTR Global
10/03/16
WELS
10/03/16
NO CHANGE
WELS
Outperform
Teva shares suffering from lack of catalysts, says Wells Fargo
Wells Fargo analyst David Maris attributes the continued slide in Teva (TEVA) shares largely to negative sector news such as the drug pricing debate, fears on generic pricing, and Mylan's (MYL) EpiPen issue, but also thinks the slide has been made worse by Teva's lack of near-term catalysts. Additionally, the ongoing Copaxone generic trial and Teva's recently filed suit against Rimsa's founders over allegedly being misled by the Mexican pharmaceutical company have added to the pressure, Maris noted. Maris acknowledges there may be "no notable catalysts" for the rest of the year for Teva, but he thinks it should be a "robust 2017" for the company and keeps an Outperform rating on the shares.
10/05/16
WELS
10/05/16
NO CHANGE
WELS
Outperform
Teva estimates lowered on generic trends at Wells Fargo
Wells Fargo analyst David Maris lowered his estimates for Teva (TEVA) for this year and next, citing expectations for lower generic sales this year and lower margins in the generic business. Maris lowered his price target range for Teva shares to $60-$61 from $70-73 based on his lower estimates as well as the uncertainty of the environment, but keeps an Outperform rating on shares citing valuation and his belief 2017 should be a better year with several pipeline events for Teva.

TODAY'S FREE FLY STORIES

INVH

Invitation Homes

$21.56

0.12 (0.56%)

15:06
06/23/17
06/23
15:06
06/23/17
15:06
Upgrade
Invitation Homes rating change  »

Invitation Homes upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
06/23/17
06/23
15:05
06/23/17
15:05
General news
NY Fed's 3-day reverse repo totaled $201.5 B with 56 counterparties »

NY Fed's 3-day…

DAL

Delta Air Lines

$52.95

0.14 (0.27%)

15:03
06/23/17
06/23
15:03
06/23/17
15:03
Hot Stocks
Delta Air Lines, Korean Air create leading trans-Pacific joint venture »

Delta Air Lines and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 30

    Jun

  • 07

    Jul

XLV

Health Care Select Sector SPDR

$80.33

-0.26 (-0.32%)

, XLK

Technology Select Sector SPDR

$56.28

0.33 (0.59%)

14:59
06/23/17
06/23
14:59
06/23/17
14:59
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

The S&P 500 (SPX) at…

XLV

Health Care Select Sector SPDR

$80.33

-0.26 (-0.32%)

XLK

Technology Select Sector SPDR

$56.28

0.33 (0.59%)

XLF

Financial Select Sector

$23.91

-0.07 (-0.29%)

XLE

Energy Select Sector SPDR

$64.16

0.21 (0.33%)

SPY

SPDR S&P 500 ETF Trust

$243.10

0.26 (0.11%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSN

Tyson Foods

$62.64

0.918 (1.49%)

14:57
06/23/17
06/23
14:57
06/23/17
14:57
Periodicals
Breaking Periodicals news story on Tyson Foods »

Hedgeye names Tyson Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAA

Plains All American

$24.53

0.6301 (2.64%)

14:50
06/23/17
06/23
14:50
06/23/17
14:50
Options
Bullish long-term option play opened in Plains All American Pipeline »

Bullish long-term option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 08

    Nov

LION

Fidelity Southern

$22.59

0.01 (0.04%)

14:46
06/23/17
06/23
14:46
06/23/17
14:46
Hot Stocks
Fidelity Southern announces appointment of Charles Christy as CFO »

Fidelity Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

14:40
06/23/17
06/23
14:40
06/23/17
14:40
General news
Fedspeak will resume with Chair Yellen »

Fedspeak will resume with…

14:30
06/23/17
06/23
14:30
06/23/17
14:30
Options
Alerian MLP attracts call buyers as shares attempt to rebound »

Alerian MLP attracts call…

LITE

Lumentum

$62.45

-0.05 (-0.08%)

14:25
06/23/17
06/23
14:25
06/23/17
14:25
Options
Lumentum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 12

    Jul

  • 13

    Jul

14:20
06/23/17
06/23
14:20
06/23/17
14:20
General news
Action Economics Survey results »

Action Economics Survey…

NTDOY

Nintendo

$42.05

0.435 (1.05%)

, SNE

Sony

$38.52

0.11 (0.29%)

14:17
06/23/17
06/23
14:17
06/23/17
14:17
Periodicals
Nintendo market cap surpasses Sony's in Japan, Nikkei reports »

Nintendo's (NTDOY)…

NTDOY

Nintendo

$42.05

0.435 (1.05%)

SNE

Sony

$38.52

0.11 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
06/23/17
06/23
14:17
06/23/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
06/23/17
06/23
14:16
06/23/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

14:15
06/23/17
06/23
14:15
06/23/17
14:15
Conference/Events
Portola Pharmaceuticals hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

SAFM

Sanderson Farms

$123.21

-2.89 (-2.29%)

14:08
06/23/17
06/23
14:08
06/23/17
14:08
Hot Stocks
Sanderson Farms to 'vigorously defend' California chicken lawsuit »

Sanderson Farms issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$60.50

3.847 (6.79%)

14:05
06/23/17
06/23
14:05
06/23/17
14:05
Options
Restoration Hardware call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:00
06/23/17
06/23
14:00
06/23/17
14:00
General news
Breaking General news story  »

Federal Reserve Board…

BLCM

Bellicum Pharmaceuticals

$13.98

1.33 (10.51%)

13:51
06/23/17
06/23
13:51
06/23/17
13:51
Recommendations
Bellicum Pharmaceuticals analyst commentary  »

Bellicum selloff after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 26

    Sep

MDRX

Allscripts

$12.71

0.52 (4.27%)

13:50
06/23/17
06/23
13:50
06/23/17
13:50
Options
Second day of bullish option flow in Allscripts »

Second day of bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$18.50

0.16 (0.87%)

13:45
06/23/17
06/23
13:45
06/23/17
13:45
Options
Nutanix call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
06/23/17
06/23
13:40
06/23/17
13:40
General news
And now Fed's Mester warns that a failure to hike »

And now Fed's Mester…

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:36
06/23/17
06/23
13:36
06/23/17
13:36
Hot Stocks
Breaking Hot Stocks news story on Portola Pharmaceuticals »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:35
06/23/17
06/23
13:35
06/23/17
13:35
Hot Stocks
Breaking Hot Stocks news story on Portola Pharmaceuticals »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

GE

General Electric

$27.59

0.035 (0.13%)

13:30
06/23/17
06/23
13:30
06/23/17
13:30
Options
19.1K GE Jul - Aug 29 call spreads sold at 12c »

19.1K GE Jul - Aug 29…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.